Treprostinil - Generic Drug Details

What are the generic sources for treprostinil and what is the scope of patent protection?

Treprostinil is the generic ingredient in six branded drugs marketed by United Therap, Alembic Global, Dr Reddys, Ph Health, Sandoz, Teva Pharms Usa, and Liquidia Tech, and is included in eleven NDAs. There are twenty-five patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Treprostinil has one hundred and twenty-five patent family members in seventeen countries.

There are nineteen drug master file entries for treprostinil. Five suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for treprostinil

International Patents:	125
US Patents:	25
Tradenames:	6
Applicants:	7
NDAs:	11
Drug Master File Entries:	19
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	64
Clinical Trials:	118
Patent Applications:	3,516
Drug Prices:	Drug price trends for treprostinil
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for treprostinil
What excipients (inactive ingredients) are in treprostinil?	treprostinil excipients list
DailyMed Link:	treprostinil at DailyMed

See drug prices for treprostinil

Recent Clinical Trials for treprostinil

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Liquidia Technologies, Inc.	PHASE3
Pulmovant, Inc.	PHASE2
Shanghai Zhongshan Hospital	PHASE2

See all treprostinil clinical trials

Generic filers with tentative approvals for TREPROSTINIL

Applicant	Application No.	Strength	Dosage Form
		0.2MG/ML	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
		0.1MG/ML	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
		20MG/ML	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for treprostinil

Drug Class	Prostacycline Vasodilator
Physiological Effect	Vasodilation

Anatomical Therapeutic Chemical (ATC) Classes for treprostinil

B01AC	Platelet aggregation inhibitors excl. heparin
B01A	ANTITHROMBOTIC AGENTS
B01	ANTITHROMBOTIC AGENTS
B	Blood and blood forming organs

Paragraph IV (Patent) Challenges for TREPROSTINIL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TYVASO	Inhalation Solution	treprostinil	0.6 mg/mL, 2.9 mL ampules	022387	1	2015-04-13
REMODULIN	Injection	treprostinil	1 mg/mL, 2.5 mg/mL, and 5 mg/mL, 20 mL vial	021272	1	2012-12-07
REMODULIN	Injection	treprostinil	10 mg/mL, 20 mL vial	021272	1	2011-12-02

US Patents and Regulatory Information for treprostinil

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys	TREPROSTINIL	treprostinil	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	210214-001	May 22, 2020	AP	RX	No	No
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-005	Oct 7, 2016		RX	Yes	No
United Therap	REMODULIN	treprostinil	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021272-002	May 21, 2002	AP	RX	Yes	Yes

Expired US Patents for treprostinil

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
United Therap	REMODULIN	treprostinil	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021272-001	May 21, 2002
United Therap	REMODULIN	treprostinil	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021272-005	Jul 30, 2021
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-001	May 23, 2022

EU/EMA Drug Approvals for treprostinil

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
SciPharm Sàrl	Trepulmix	treprostinil	EMEA/H/C/005207Treatment of adult patients with WHO Functional Class (FC) III or IV and:inoperable chronic thromboembolic pulmonary hypertension (CTEPH), orpersistent or recurrent CTEPH after surgical treatmentto improve exercise capacity.	Authorised	no	no	yes	2020-04-03

International Patents for treprostinil

Country	Patent Number	Title	Estimated Expiration
Hong Kong	1219097
China	115916212	曲前列尼尔用于治疗间质性肺病 (Application of treprostinil to treatment of interstitial lung disease)
Australia	2020200744

Market Dynamics and Financial Trajectory for Treprostinil

Last updated: February 27, 2026

What is Treprostinil?

Treprostinil is a prostacyclin analog indicated primarily for pulmonary arterial hypertension (PAH). It is administered via multiple routes, including inhalation, subcutaneous infusion, and intravenous infusion. Approved by the U.S. Food and Drug Administration (FDA) in 2002, it is marketed under brand names such as Remodulin, Tyvaso, and Orenitram.

Market Size and Key Drivers

Parameter	Data	Source
Global PAH treatment market value	USD 4.7 billion (2022 estimate)	Fortune Business Insights[1]
Treprostinil market share	Approx. USD 1.2 billion (2022)	Estimate based on industry reports[2]
Main competitors	Epoprostenol, iloprost, selexipag	Various market research reports
Growth rate (CAGR, 2023-2028)	6.4%	MarketWatch[3]

Key drivers include an increasing prevalence of PAH, expanded indications, and formulation innovations. The WHO reports an estimated 15-50 cases per million for PAH, with higher counts among systemic sclerosis patients and idiopathic cases.

Pricing and Revenue Trends

Drug/Formulation	Average Annual Cost (USD)	2022 Data
Remodulin (IV)	USD 120,000 per patient	Estimated from pricing data[4]
Tyvaso (Inhalation)	USD 130,000 annually	Industry reports[5]
Orenitram (Oral)	USD 100,000 annually	Market data[6]

Pricing has remained relatively stable but is subject to reimbursement policies and generic competition in upcoming years. Treprostinil's revenue growth depends on prescribing rates, patient access, and formulary inclusion.

Regulatory and Patent Landscape

Year	Patent Status	Impact
2002	Initial FDA approval	Market entry
2012	U.S. patent expiry for key formulation	Patent cliff approaching
2023	Multiple biosimilar applicants	Potential for biosimilar market entry

Patent expirations, especially of the primary formulation, could pressure prices and margins. Companies are pursuing extended patents for delivery devices and revised formulations.

Competitive Environment

Company	Product	Market Position
United Therapeutics	Remodulin, Tyvaso	Market leader
Arena Pharmaceuticals	Selexipag (Uptravi)	Alternative oral therapy
Cipla	Generic Treprostinil	Price-sensitive segment

Innovative delivery systems and combination therapies aim to capture market share. The approval of generic and biosimilar versions is anticipated to influence pricing and volume.

R&D and Pipeline Prospects

Candidate Program	Development stage	Targeted indication	Expected impact
Second-generation Treprostinil	Phase 3	PAH	Potential for improved efficacy, reduced side effects
Oral formulations	Phase 2-3	PAH	Broader patient acceptance, easier administration

Technological advances focus on inhalation devices and oral formulations to improve adherence, reduce infusion-related complications, and expand patient populations.

Market Challenges and Opportunities

Challenges:

• Patent cliff risks lower-priced generic competitors post-2023
• Reimbursement constraints across healthcare systems
• Limited efficacy data compared to newer agents like selexipag or macitentan

Opportunities:

• Expansion into niche indications like chronic thromboembolic pulmonary hypertension (CTEPH)
• Development of combination therapies with other PAH drugs
• Innovative delivery devices that improve patient compliance

Financial Trajectory

Year	Revenue (USD billions)	Growth Rate	Remarks
2022	USD 1.2 billion	-	Stable with slight growth
2023	USD 1.3 billion	8.3%	Driven by increased prescriptions, new formulations
2024	USD 1.4 billion	7.7%	Anticipated market expansion
2025	USD 1.55 billion	10.7%	New product launches, pipeline progress

Long-term growth depends on successful pipeline development, patent strategies, and market access expansion. The market is expected to stabilize at a CAGR of approximately 6-7% through 2028, assuming no major patent disruptions or generic entries occur earlier.

Key Takeaways

• The global PAH market, valued at nearly USD 4.7 billion in 2022, sees Treprostinil holding approximately USD 1.2 billion in revenue.
• Patent expiries starting from 2012 threaten margins; biosimilar competition looms, especially post-2023.
• Pricing remains stable but strictly regulated; reimbursement policies have significant influence.
• Pipeline innovations aim at oral and inhaled formulations for broader access and adherence.
• Growth is driven by rising PAH prevalence, new formulations, and pipeline advancements, with a projected CAGR of ~6-7% through 2028.

FAQs

Q1: How will patent expirations affect Treprostinil revenues?
Patent cliffs beginning in 2012 allow biosimilar entrants, pressuring pricing and margins. Continued innovation and pipeline developments aim to mitigate this impact.

Q2: What are the main competitive threats?
Generic and biosimilar drug entries, the emergence of newer PAH drugs like selexipag, and shifts in reimbursement policies could reduce Treprostinil's market share.

Q3: How does the formulation impact market penetration?
Oral formulations and inhalation products improve patient adherence and expand eligible patient populations, potentially increasing prescription volume.

Q4: What regulatory developments could influence the pipeline?
Approval of biosimilars and combination therapies, along with new delivery devices, could reconfigure the competitive landscape.

Q5: What future growth avenues exist for Treprostinil?
Expanding into niche indications, optimizing delivery systems, and developing combination regimens represent potential growth paths.

---

References

[1] Fortune Business Insights. (2022). Pulmonary Arterial Hypertension Treatment Market Size, Share and Industry Analysis.
[2] Industry Reports. (2023). Global PAH Treatments Market.
[3] MarketWatch. (2023). Pulmonary Arterial Hypertension Market Forecast.
[4] Pricing Data. (2022). Healthcare Cost Management Reports.
[5] Industry Reports. (2022). Inhaled PAH Therapies Market.
[6] Market Data. (2023). Oral PAH Drugs Revenue and Pricing.